{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:12:43Z","timestamp":1788405163900,"version":"build-2803163510"},"reference-count":48,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hypothyroidism is a recognized adverse effect of cancer therapies such as immune checkpoint inhibitors (ICI), tyrosine kinase inhibitors (TKI), and radiotherapy. Although proposed as an indicator of treatment response, its prognostic significance across cancer types and therapies remains underexplored. This study evaluated survival outcomes associated with treatment-induced hypothyroidism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using de-identified electronic health record data from the University of Michigan (2006\u20132023). Adults (\u226518 years) receiving ICIs, TKIs, or radiotherapy, without prior thyroid disease or malignancy, were included. We defined hypothyroidism by institutional laboratory criteria or thyroid hormone initiation. Time-dependent Cox models estimated hazard ratios (HRs) and 95% confidence intervals for overall and cancer-specific survival, adjusting for demographic, clinical, and lifestyle factors. Analyses were stratified by treatment class and cancer sites; sensitivity analyses assessed robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 9909 patients (57,772 person-years; median follow-up 4.64 years), 2177 (22.0%) developed hypothyroidism (median onset time: 5.04 months). Treatment-induced hypothyroidism was associated with improved overall (HR = 0.86 [0.79\u20130.93],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001) and cancer-specific survival (HR = 0.76 [0.70\u20130.84],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001). Stratified analyses showed significant survival benefits with hypothyroidism following ICI (overall HR = 0.75 [0.61\u20130.92],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.014; cancer-specific HR = 0.75 [0.66\u20130.94],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.012) and radiotherapy (overall HR = 0.88 [0.81\u20130.96],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.011; cancer-specific HR = 0.76 [0.68\u20130.84],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001), but not for TKI. Site-specific survival benefits were observed in brain\/central nervous system (HR = 0.39 [0.26\u20130.61],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001), lip\/oral cavity\/pharyngeal (HR = 0.77 [0.61\u20130.97],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.032), and lung\/bronchus cancers (HR = 0.80 [0.66\u20130.97],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.034) but higher mortality in colon cancer (HR = 1.82 [1.10\u20133.02],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.021). Results were consistent across sensitivity analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Hypothyroidism after ICI and radiotherapy was associated with improved survival, supporting its potential as a prognostic biomarker of therapeutic benefit. Future studies should investigate the underlying mechanisms and clinical implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10507256261449473","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T12:48:26Z","timestamp":1778330906000},"page":"597-608","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival Outcomes Associated with Hypothyroidism Following Cancer Therapies"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2702-3533","authenticated-orcid":false,"given":"Harry D.","family":"Momo","sequence":"first","affiliation":[{"name":"Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan R.","family":"Haymart","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Mondul","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.2.8182"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk008"},{"key":"e_1_3_4_4_1","article-title":"Hypothyroidism as a predictive biomarker for survival benefits in advanced colorectal cancer patients treated with Apatinib-based therapy","volume":"16","author":"Zhong Y","year":"2025","unstructured":"3.Zhong Y, , Wu J, , Guo F, et al. Hypothyroidism as a predictive biomarker for survival benefits in advanced colorectal cancer patients treated with Apatinib-based therapy. Front Pharmacol 2025;16.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-019-00672-2"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0201"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr275"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000337079"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01004-8"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12539-019-00337-8"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01871-7"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03151-2"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02802-6"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02664-y"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2018.07.002"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.132.10.1041"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2015.6.2.2"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1172"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.0308"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03718-2"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-018-9463-2"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrv006"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174321"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.12074"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.01.029"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.03.011"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/725410"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113949"},{"key":"e_1_3_4_30_1","unstructured":"29.AI & Digital Health innovation. Deidentified research data. AI & Digital Health Innovation; 2025. Available from: https:\/\/aidhi.umich.edu\/deidentified-research-data [Last accessed: April3 2025]."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-24-0328"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.12.008"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.4158\/1934-2403-22.11.1358"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.126.5.652"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011201)92:11<2892::AID-CNCR10134>3.0.CO;2-T"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2019.1665206"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrx054"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-020-02260-5"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.793234"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0075"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03128-7"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1375642"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076514"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343020"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2012.08.002"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0231"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3651"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2012.01.010"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256261449473","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10507256261449473","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256261449473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:15:31Z","timestamp":1788401731000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10507256261449473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1177\/10507256261449473"],"URL":"https:\/\/doi.org\/10.1177\/10507256261449473","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]}}}